Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Siyi Zou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6196-6306; OpenAlex author ID A5034900484. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 5 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 12

  1. Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development. Co-author DOI 10.1016/j.cmet.2025.07.008↗
  2. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Co-author DOI 10.1038/s41418-024-01423-1↗
  3. Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes. Co-author DOI 10.1016/j.canlet.2024.217134↗
  4. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1097/js9.0000000000000264↗
  5. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study. Co-author DOI 10.1186/s12885-022-09719-6↗
  6. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-022-01272-w↗
  7. Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort. Co-author DOI 10.1016/j.ebiom.2021.103716↗
  8. Preoperative plasma D-dimer independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing radical resection. Co-author DOI 10.1186/s12957-021-02281-8↗
  9. Positive feedback between lncRNA FLVCR1-AS1 and KLF10 may inhibit pancreatic cancer progression via the PTEN/AKT pathway. Co-author DOI 10.1186/s13046-021-02097-0↗
  10. Preoperative Plasma D-Dimer Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Radical Resection Co-author DOI 10.21203/rs.3.rs-308863/v1↗
  11. A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.634881↗
  12. Accuracy of Nodal Positivity in Inadequate Lymphadenectomy in Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Population Study Using the US SEE… Co-author DOI 10.3389/fonc.2019.01386↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 10 shared papers, 2019–2025 · strength 1.43
  2. Xiaxing Deng · 8 shared papers, 2019–2024 · strength 1.06
  3. Chenlei Wen · 7 shared papers, 2021–2025 · strength 1.00
  4. Hao Chen · 5 shared papers, 2019–2022 · strength 0.59
  5. Pengyi Liu · 3 shared papers, 2022–2025 · strength 0.51
  6. Chenghong Peng · 4 shared papers, 2021–2023 · strength 0.47
  7. Jiewei Lin · 3 shared papers, 2021–2025 · strength 0.46
  8. Haoda Chen · 3 shared papers, 2021–2022 · strength 0.44
  9. Jun Zhang · 3 shared papers, 2021 · strength 0.38
  10. Jiayu Lin · 2 shared papers, 2025 · strength 0.38
  11. Qian Zhan · 3 shared papers, 2021–2022 · strength 0.37
  12. Xiongxiong Lu · 3 shared papers, 2021–2023 · strength 0.37
  13. Jiancheng Wang · 3 shared papers, 2021–2023 · strength 0.36
  14. Yangbing Jin · 3 shared papers, 2021–2023 · strength 0.35
  15. Yihao Liu · 2 shared papers, 2022–2025 · strength 0.33
  16. Hao Chen · 2 shared papers, 2021–2024 · strength 0.32
  17. Yizhi Cao · 2 shared papers, 2022–2025 · strength 0.32
  18. Qian Zhan · 2 shared papers, 2022–2024 · strength 0.32
  19. Shuyu Zhai · 2 shared papers, 2021–2025 · strength 0.30
  20. Lingxi Jiang · 2 shared papers, 2021–2024 · strength 0.30
  21. Yu Jiang · 2 shared papers, 2019–2025 · strength 0.29
  22. Baiyong Shen · 2 shared papers, 2021–2023 · strength 0.27
  23. Henghui Zhang · 2 shared papers, 2021–2023 · strength 0.22
  24. Dongfeng Cheng · 2 shared papers, 2021–2023 · strength 0.22
  25. Jiabin Jin · 2 shared papers, 2021–2023 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.